Veraguensin shows activity against trypomastigote T. cruzi., it shows high antileishmanial activity. Veraguensin and galgravin can inhibit bone resorption and may offer novel compounds for the development of drugs to treat bone-destructive diseases such as osteoporosis. Veraguensin is a lignan. It has a role as a metabolite.

Rubiadin-1-methyl ether probed as Type I photosensitizers. Rubiadin 1-methyl ether decreases the number of parasites (schizonts) in a dose-dependent manner, and 100% of inhibition was obtained with 30 to 40 micrograms. Rubiadin-1-methyl ether shows strong enhancing activity for adipocyte differentiation, it could be beneficial in the treatment of diabetes. Rubiadin-1-methyl ether has therapeutic potential against osteoporosis, it can promote osteoblast proliferation and inhibit osteoclast TRAP activity and bone resorption, and the inhibitory effects on osteoclastic bone, antiosteoporotic activity of M. officinalis .

Diphyllin could be characterized as a new V-ATPase inhibitor in treating gastric cancer and inhibiting the phosphorylation of LRP6 in Wnt/β-catenin signaling. Diphyllin has anti-inflammatory activities, it shows 50% inhibition of NO production from peritoneal macrophages. Diphyllin also has in vitro antileishmanial activity, it exerts a strong specific inhibitory activity (IC50 = 0.2 microM) resulting from the inhibition of parasite internalization within macrophages.